ABSTRACT (E)-2Ј-deoxy-2Ј-(fluoromethylene)cytidine (FMdC) is a new analog of deoxycytidine with promising anticancer activity. We investigated the action of FMdC on DNA metabolism by evaluating its incorporation into DNA, its excision from DNA in vitro, and the role of the incorporation of FMdC into DNA in causing cytotoxicity. In vitro DNA primer extension demonstrated that FMdC nucleotides were incorporated with relatively high substrate efficiency into the C sites of the elongating DNA strand. Once incorporated, FMdC became a poor substrate for further chain elongation by DNA polymerases, resulting in a termination of DNA synthesis at the sites of incorporation. Furthermore, the 3Ј 3 5Ј exonuclease activity of DNA polymerase ⑀ or wild-type p53 protein was ineffective in removing the incorporated FMdC from DNA in vitro. FMdC also showed potent cytotoxic activity against human leukemia and solid tumor cells. Incubation with a low concentration of FMdC (10 nM) induced cell cycle arrest at S or G 1 phases, but the cells eventually died as the time of incubation increased. Compared with HL-60 cells, human myeloid ML-1 cells with wild-type p53 were more sensitive to FMdC, but the S or G 1 phase arrest did not seem to depend on the presence or absence of p53. Inhibiting the incorporation of FMdC into cellular DNA by aphidicolin suppressed the cytotoxic effect of the compound. We conclude that the incorporated FMdC nucleotide profoundly disrupts DNA synthesis and resists excision by exonucleases, and that incorporation of this analog into DNA is a key molecular event responsible for the drug's cytotoxicity.
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(E)-2Ј-Deoxy-2Ј-(fluoromethylene)cytidine (FMdC) is a novel deoxycytidine analog developed as a specific inhibitor of ribonucleotide reductase (McCarthy et al., 1991) . Early studies demonstrated that the diphosphate of this compound affects ribonucleotide reductase through a mechanism-based inhibition (van der Donk et al., 1996) similar to that of gemcitabine. However, unlike gemcitabine and 1-␤-D-arabinofuranosylcytosine, FMdC is relatively resistant to deamination by cytidine deaminase . This favorable metabolic property may contribute in part to the analog's potent anticancer activity. In vivo pharmacology study in animals demonstrated that at the dose of 200 and 400 mg/kg, FMdC is eliminated from the plasma and normal tissue with a plasma half-life (t 1/2 ) of about 60 min. The kidney is shown to be the major site of initial distribution of FMdC (Adams et al., 1996) . After entering the cells, FMdC is first converted to its 5Ј-monophosphate and is then further phosphorylated to diphosphate and triphosphate. The nucleotides of FMdC are thought to be the active metabolites of this drug. The diphosphate of FMdC has been shown to inhibit ribonucleotide reductase, whereas the triphosphate seems to directly interfere with DNA polymerization (for review, see Seley, 2000) . It has been demonstrated that FMdC displays a strong cytotoxic activity against a variety of human solid tumor cell lines in culture and shows a potent antitumor activity against murine tumor models and human tumor xenografts in nude mice (Bitonti et al., 1994 (Bitonti et al., , 1995 Snyder, 1994; Piepmeier et al., 1996; Wright et al., 1996; Sun et al., 1997 Sun et al., , 1998 Takahashi et al., 1998; Kotchetkov et al., 1999) . Clinical trials of FMdC, known as tezacitabine, have recently begun in patients with hematological malignancies and solid tumors (Noriyuki et al., 1999; Rodriguez et al., 1999; Faderl et al., 2000) .
Many therapeutic nucleoside analogs share similar metabolic pathways and pharmacological actions. After entering the cells, nucleoside analogs are metabolically converted to nucleotides through a series of sequential phosphorylation steps. The analog nucleotides are believed to be the active forms of the drugs, which in many cases have multiple sites of action in the cells. For example, ribonucleotide reductase and DNA polymerases are inhibited by the diphosphate and triphosphate of gemcitabine and fludarabine (Gandhi et al., 1994; Hui and Reitz, 1997; Storniolo et al., 1997) . Fludarabine also inhibits DNA ligation, DNA-dependent RNA primer formation, and RNA synthesis Yang et al., 1992; Catapano et al., 1993) . Despite these multiple sites of action, incorporation of the analogs into DNA, which results in the termination of DNA synthesis, seems to be the most prominent event and is closely associated with the cytotoxic action of the analogs. Inhibition of the incorporation of analogs into DNA usually leads to a significant reduction of the analog-induced cell death .
Like other nucleoside analogs, FMdC seems to have multiple sites of action. The inhibition of ribonucleotide reductase by FMdC diphosphate has been well characterized (van der Donk et al., 1996; Kanazawa et al., 1998) . In vitro studies suggest that the triphosphate of FMdC may inhibit human DNA polymerase (pol) ␣ and cause a pause in further DNA synthesis (Yonetani and Mizukami, 1996) . However, the incorporation of FMdC triphosphate into DNA and its biological significance have not been systemically evaluated. In this study, we investigated the incorporation of FMdC triphosphate into DNA and its consequences in vitro and in whole cells. We also examined the ability of DNA pol ⑀ and p53, two cellular molecules with intrinsic 3Ј 3 5Ј exonuclease activity, to remove the incorporated FMdC from DNA in vitro.
Materials and Methods
Chemicals and Reagents. FMdC and its triphosphate (FMdCTP) were provided by Dr. H. S. Gill (Hoechst Marion Roussel, Inc., Cincinnati, OH). Propidium iodide was obtained from Sigma Chemical (St. Louis, MO), RNase and proteinase K from Roche Molecular Biochemicals (Indianapolis, IN), and ethidium bromide from Bio-Rad (Hercules, CA). The 17-base M13 sequencing primer (5Ј-GTAAAAC-GACGGCCAGT-3Ј) and high-performance liquid chromatographypurified dATP, dCTP, dGTP, and dTTP were obtained from Amersham Biosciences, Inc. (Piscataway, NJ). The 25-base template (5Ј-CACACACGACTGGCCGTCGTTTTAC-3Ј) was synthesized by Genosys Biotechnologies, Inc. (The Woodlands, TX). [␥-32 p]ATP (specific activity 4500 Ci/mmol) was purchased from ICN Radiochemicals, Inc. (Irvine, CA). T4 polynucleotide kinase and the large fragment of Escherichia coli DNA polymerase I (Klenow fragment) were obtained from United States Biochemical Corp. (Cleveland, OH). DNA polymerases ␣ (pol ␣) and ⑀ (pol ⑀) were purified from human T-lymphoblastoid cells and characterized as described previously (Huang et al., 1990) . The wild-type (wt) p53 protein was purified from human leukemia ML-1 cells by precipitation of the protein extracts with 50 mM (NH 4 ) 2 SO 4 , followed by fractionation with the Pharmacia fast-performance liquid chromatography system using a MonoQ column with a linear gradient of 20 to 700 mM NaCl in 50 mM Tris buffer (1 ml/min/fraction, 40 min). The p53 protein in the fractions was characterized as described previously (Huang, 1998) . Fraction 25 was found to contain the highest level of p53 protein with 3Ј 3 5Ј exonuclease activity. Immunodepletion of p53 by anti-p53 antibody (Ab-6; Oncogene Science, Cambridge, MA) also removed the 3Ј 3 5Ј exonuclease activity from this fraction. Thus, fraction 25 was used for the excision assays in this study.
Cell Culture. Human leukemia cell lines HL-60 and ML-1 were maintained in suspension culture RPMI 1640 medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere containing 5% CO 2 . During exponential growth, the population doubling time was approximately 22 h. All experiments were carried out using exponentially growing cell cultures. The cell lines were tested periodically to ensure that they were free from Mycoplasma species. Cytotoxicity Assays. Cell growth inhibition was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. HL-60 or ML-1 cells were seeded onto 96-well plates at the initial density of 4000 cells/well. After incubation with various concentrations of FMdC for 72 h, 50 l of MTT reagent (3 mg/ml) was added to each well, and incubation was continued for another 4 h. The cells were then centrifuged (1500 rpm, 10 min), and the medium was removed. The cell pellets were dissolved in 200 l of dimethyl sulfoxide. Absorbance was measured at 570 nm within 1 h, using the Dynatech MR 5000 plate reader (Dynatech Labs, Chantilly, VA). The percentage of growth inhibition was calculated by dividing the absorbance of each FMdC-treated well by that of the untreated control. The antiproliferative activity was expressed as the drug concentration that induced 50% growth inhibition (IC 50 ).
To examine the change in cell morphology, the FMdC-treated cells were centrifuged (550 rpm, 5 min) onto glass slides, using a Shandon-Elliot cytospin (London, UK). The slides were fixed with 100% methanol for 45 min, air-dried, and then stained with Wright's Giemsa stain solution (Biochemical Sciences Inc., Swedesboro, NJ). Cells were examined for morphological changes characteristic of apoptosis. Photomicrographs were taken using a 20ϫ objective (Nikon, Tokyo, Japan).
Apoptosis was further confirmed by a DNA fragmentation assay. After treatment with FMdC, approximately 5 ϫ 10 6 cells were collected, and the cell pellets were digested in 1 ml of buffer containing 10 mM Tris-HCl, pH 7.8, 100 mM NaCl, 25 mM EDTA, 0.5% SDS, and 10 l of proteinase K (1 mg/ml, added fresh) at 45°C overnight. The samples were analyzed on 1.8% agarose gel in 1ϫ Tris-borate/ EDTA buffer (100 mM Tris-borate, pH 8.3, 2 mM EDTA). After electrophoresis, the gel was incubated overnight in 400 ml of 0.1ϫ Tris-borate/EDTA buffer containing 20 l of RNase (500 g/ml) and then photographed. DNA bands were quantitated using the ChemiImager 4400 imager system (Alpha Innotech Corporation, San Leandro, CA).
Cell Cycle Analysis by Flow Cytometry. Exponentially growing cells were exposed to 10 nM FMdC for 6, 12, 24, 36, or 48 h, washed with cold phosphate-buffered saline (PBS; 135 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 8 mM Na 2 HPO 4, pH 7.4), and resuspended in PBS at 10 6 cells/ml. The cells were fixed in 70% ethanol at Ϫ20°C overnight, washed twice with cold PBS, and stained with 1 ml of PBS containing propidium iodide (15 g/ml), Tween 20 (0.5%), and 5 l of RNase (500 g/ml). The DNA content was measured using a FACSVantage flow cytometer (BD Biosciences, San Jose, CA). Data acquisitions and analyses were performed using Cell-Quest software (BD Biosciences).
Preparation of 18-Base Oligomer with an Incorporated FMdC Nucleotide at 3 End. The 17-base M13 universal sequencing primer was labeled at the 5Ј end with [␥-32 P]ATP using the T4 polynucleotide kinase and then annealed to the 25-base template as described previously (Huang et al., 1990) . The sequence of 32 Plabeled 17-base primer/25-base template hybrid was as follows: (5Ј) 32 P-GTAAAACGACGGCCAGT (3Ј) CATTTTGCTGCCGGTCAGCA-CACAC.
This hybrid was incubated with 10 M FMdCTP and DNA pol I at 37°C for 30 min. The reaction product was separated by electrophoresis through a 10% polyacrylamide sequencing gel, and the band containing the 18-base DNA oligomer with FMdC incorporated at its 3Ј end was excised from the gel. The oligomer was eluted from the gel slice by first smashing the gel slice into small pieces, followed by incubating in 0.5 M NH 4 Ac and 1 mM EDTA at 45°C for 2 h with occasional stirring. The eluted 18-oligomer was precipitated with 80% ethanol and annealed to the 25-base template. The radioactivity of both the labeled 17-base/template and 18-base/template hybrids was determined by liquid scintillation counting, and the specific radioactivity was calculated based on the oligomer concentrations and the respective radioactivity.
DNA Primer Extension Assay. The 17-base primer/template and 18-base primer/template hybrids were used as the substrates for Action of FMdC on DNA Metabolism DNA primer extension assays by DNA pol ␣ and pol I. The reaction mixtures contained 20 mM Tris-HCl, pH 7.5, 8 mM MgCl 2 , 0.5 mM dithiothreitol, 10 mM NaCl, bovine serum albumin (20 g/ml), and the labeled DNA substrates at various concentrations, dNTPs, FMdCTP, as well as pol I or pol ␣. The reactions were incubated at 37°C for 30 min and analyzed by electrophoresis through a 10% polyacrylamide sequencing gel. After autoradiography, the radioactivity of each DNA band in the gel was quantitated using a gel analyzer (InstantImager; Packard Instrument Co., Meriden, CT).
DNA Excision Assay. The 17-and 18-base primer/template hybrids were used as the substrates for excision by 3Ј 3 5Ј exonuclease associated with human pol ⑀ and wt p53 protein. The reaction mixtures contained 20 mM Tris-HCl, pH 7.5, 8 mM MgCl 2 , 0.5 mM dithiothreitol, 10 mM NaCl, bovine serum albumin (20 g/ml), and various concentrations of the labeled DNA substrates, as well as pol ⑀ or p53. The reactions were incubated at 37°C for 30 min and analyzed by electrophoresis through a 10% polyacrylamide sequencing gel. After autoradiography, the radioactivity of the DNA bands in the gel was quantitated by the InstantImager. The K m and V max values from three separate experiments were calculated based on the Michaelis-Menten equation, using the Winzyme computer program (Biosoft, Ferguson, MO).
Results
Incorporation of FMdC Nucleotide into DNA. Because most nucleoside analogs cause cytotoxicity after being incorporated into cellular DNA, we first tested the ability of human DNA pol ␣ to incorporate FMdCTP into DNA in vitro, using a primer extension assay with the 32 P-labeled 17-/25-base hybrid as the primer/template. As illustrated in Fig. 1A , FMdCTP was incorporated into the C site of the primer strand at position 18 by pol ␣ in the absence of dNTPs (lanes 2 and 3). In the presence of each of the 4 dNTPs at a concentration of 0.5 M, increasing concentrations of FMdCTP competed with dCTP for incorporation, resulting in a concentration-dependent pause of DNA extension at position 18 and a reduction of the full-length products (lanes 4-7). Evaluation of DNA pol I indicated that FMdCTP competed poorly with dCTP, as evidenced by the efficient elongation of the strand to the full-length product in the presence of various concentrations of FMdCTP (Fig. 1B, lanes 4-7) . Even at the FMdCTP/dCTP ratio of 20:1 (10:0.5 M), no significant reduction of the full-length product was seen (lane 7). Thus, FMdCTP seemed to be a better substrate for human DNA pol ␣ than for the E. coli enzyme, which strongly preferred normal dNTPs as the substrates. However, in the absence of dNTPs, pol I was still able to incorporate FMdCTP into the DNA (Fig.  1B, lanes 2 and 3) .
Because FMdCTP seemed to be a relatively good substrate for pol ␣, we further compared its incorporation kinetics with that of dCTP catalyzed by pol ␣. Various concentrations of FMdCTP or dCTP were incubated with pol ␣ and the 32 Plabeled primer/template, and the reaction products were analyzed. As shown in Fig. 1C , we observed a concentrationdependent incorporation of FMdCMP or dCMP into position 18. When the radioactivity of each band was quantitated (Fig. 1D) , dCTP seemed to be a somewhat better substrate for pol ␣ than was FMdCTP.
DNA Chain Termination by FMdC Nucleotide. To further characterize the chain termination properties of FMdC, we prepared an 18-base primer containing a FMdCMP at the 3Ј end of the oligomer and annealed it to the 25-base template as described under Materials and Methods. This analog-primer/template hybrid was used as the substrate for extension by pol ␣ and pol I, in comparison with the normal 17-base primer/template. As shown in Fig. 2A , both pol ␣ and pol I extended the normal DNA substrate efficiently in the presence of four normal dNTPs. In contrast, the presence of FMdCMP at the 3Ј end of the primer substantially inhibited strand elongation by each enzyme. Small amounts of extension products were detected in samples incubated with pol I for prolonged periods (30-40 min); no significant extension was observed in samples incubated with pol ␣. The time courses of primer extension of both normal and analog-terminated primers by pol ␣ and pol I are shown in Fig. 2B .
To further characterize the extension in samples with the normal (17-base) primer and the analog-containing (18-base) primer, we incubated various concentrations of the DNA substrates with pol ␣. We observed a concentration-dependent increase of extension products in samples with the normal DNA substrate (Fig. 2C, lanes 2-8) , whereas the extension of the analog primer was hardly detectable (lanes 10-16). The quantitative data are shown in Fig. 2D . Kinetic analysis revealed an apparent K m value of 76.9 nM for the normal 17-base primer as the substrate for pol ␣. Because of inadequate primer extension, we were unable to determine the K m value for the analog-containing primer. 
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Excision of FMdC from 3 End of DNA by pol ⑀ and p53. Because FMdC showed potent DNA chain termination activity in vitro (Fig. 2) , we sought to determine whether the incorporated analog could be removed from DNA by enzymes. Two proteins, DNA pol ⑀ and the wt p53, each with intrinsic 3Ј 3 5Ј exonuclease activity (Mummenbrauer et al., 1996; Burgers, 1998) , were tested for their abilities to remove FMdCMP from the 3Ј terminus of the 18-base primer when annealed to the 25-mer template. The 3Ј-FMdCMP primer was prepared as described above; the normal 17-base primer was processed through the same procedures and used as a control. As shown in Fig. 3A , pol ⑀ effectively removed the normal nucleotides from the 17-base primer; most of the 17-mers were degraded to shorter oligonucleotides within 15 min. The p53 protein exhibited moderate activity in excising nucleotides from the 17-base primer; about 50% of the 17-mers still remained intact after a 45-min incubation. When the 18-base primer containing 3Ј-terminal FMdCMP was used as the substrate, pol ⑀ and p53 each showed a substantially reduced ability to remove the analog from the 18-base primer. Figure 3B shows a quantitative comparison of the time courses of excision of the normal 17-base primer and the FMdCMP-18-mer by pol ⑀ and p53. Clearly, the FMdCMPcontaining DNA was a poor substrate for excision by either enzyme.
The substrate efficiency of the normal 17-base primer/ template and the 3Ј-FMdCMP-containing 18-base primer/ template for excision by pol ⑀ and p53 was further characterized using a kinetic assay. Various concentrations of each primer/template were incubated with each enzyme, and the excision products were quantitated (Fig. 3, C and D) . The generation of excision products by each enzyme was concentration-dependent with both substrates, although the 18-base primer with FMdCMP incorporated at its 3Ј end was much more resistant to excision by both enzymes than was the normal 17-base primer. The apparent kinetic parameters were calculated based on the primer/template substrate concentrations and the respective radioactivity associated with the excision products. As shown in Table 1 , in the case of pol ⑀, the apparent K m value for the normal 17-base primer (4.7 nM) was substantially greater than that for the FMdCMPprimer (0.4 nM), whereas the V max for excision of the FMdCMP was only 3% of that for excision of dCMP. Similarly, for p53, there was a much greater affinity for the analog-containing oligonucleotide, as measured by the apparent K m values of the normal 17-base primer (26.1 nM) and the 18-base primer (2.0 nM). As with pol ⑀, the V max for removal of FMdCMP was less than 6% of that for the removal of dCMP. Thus, although the affinity of the repair activities was substantially greater for the analog-terminated DNA than for normal primers, the rates at which pol ⑀ and p53 were able to excise the fraudulent nucleotide was greatly diminished relative to the deoxynucleotide. Fig. 2 . Extension of 3Ј-FMdCMP-terminated DNA. The oligomer (18-base primer) with FMdCMP incorporated at the 3Ј end was constructed as described under Materials and Methods. The normal 17-base primer/template was used as the control. The primer extension reactions were carried out as described under Materials and Methods. A, normal 17-base and FMdCMP-terminated 18-base primer extension reactions by pol ␣ and pol I were measured at 10, 20, 30, and 40 min. B, extension activity was measured by quantitating the radioactivity associated with the excision products and expressed as the percentage of the total input radioactivity. F, 17-mer, pol ␣; OE, 17-mer, pol I; f, 18-mer, pol ␣; ࡗ, 18-mer, pol I. Data are presented as the mean Ϯ S.D. from three separate experiments. C, kinetic assay was performed for 17-base or 18-base primer extension by pol ␣. Lane 1, the normal 17-base primer/template alone; lanes 2 to 8, reactions with 0.05, 0.1, 0.2, 0.5, 1.0, 1.5, and 2.0 nM 17-base primer, respectively; lane 9, the 18-base primer/template alone; lanes 10 to 16, reactions with 0.05, 0.1, 0.2, 0.5, 1.0, 1.5, and 2.0 nM 18-base primer, respectively. D, quantitation of the radioactivity associated with primer extension products. The extension activity was expressed as the extended radioactivity in cpm. F, 17-mer; OE, 18-mer. Data are presented as the mean Ϯ S.D. from three separate experiments.
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Cellular Responses to FMdC Treatment. Incubation of human leukemia HL-60 and ML-1 cells in various concentrations of FMdC in vitro caused a potent growth inhibition in both cell lines, although it seemed that the ML-1 cells were more sensitive to FMdC than HL-60 cells (Fig. 4A) . The drug concentrations required to achieve IC 50 during a continuous 72-h incubation were 10.4 nM for HL-60 cells and 3.5 nM for ML-1 cells. A colony formation assay showed that FMdC also exhibited potent activity in human pancreatic cancer cells. Incubation of Panc-1 cells with FMdC substantially inhibited the ability of the cells to form colonies, with IC 50 values of 148.4 nM after a 24-h incubation and 11.8 nM after continuous (10-d) exposure (data not shown).
Because FMdC showed potent DNA chain termination activity in vitro, we used a flow cytometric analysis to determine whether incubation of cells in FMdC caused changes in cell-cycle distribution (Fig. 4B) . After exposing HL-60 cells to 10 nM FMdC, we observed a time-dependent accumulation of cells in the S phase up to 24 h. Thereafter, cell death occurred, as evidenced by the appearance of a cell population with sub-G 1 DNA content. By 48 h, approximately 50% of the cells had shifted to the sub-G 1 region with a concomitant decrease of the S phase cell population. Incubation of ML-1 cells with 10 nM FMdC caused a moderate accumulation of G 1 cells (i.e., from 45 to 55%) during the first 12 h, followed by the appearance of a population of cells in the sub-G 1 region (Fig. 4C) . Consistent with the results of the MTT assay (Fig. 4A) , ML-1 cells were more sensitive to FMdC, and evidence of cell death became apparent after 12 h of incuba- Fig. 3 . Excision of incorporated FMdC from DNA. The oligomer (18-base primer) with FMdCMP incorporated at the 3Ј end was constructed as described under Materials and Methods. The normal 17-base primer was used as the control. The primer excision reactions were carried out as described under Materials and Methods. A, 17-and 18-base primer excision reactions by pol ⑀ and p53 were measured at 15, 30, and 45 min. B, graph shows the quantitation of radioactivity. The excision activity was expressed as the percentage of total input radioactivity. F, 17-mer, pol ⑀; OE, 17-mer, p53; f, 18-mer, pol ⑀; f, 18-mer, p53. Data are presented as the mean Ϯ S.D. from three separate experiments. Kinetic assay for 17-or 18-base primer excision by pol ⑀ (C) and p53 (D). The concentrations of 17-and 18-base primers are indicated. Various concentrations of the normal 17-base primer/template and 3Ј-FMdCMP-18-base primer/template were incubated with purified either pol or p53 in excision reactions for 30 min as described under Materials and Methods, and the excision products were quantitated. Values were calculated using the Michaelis-Menten equation. Each data point represents the mean Ϯ S.D. of three separate experiments.
Enzyme
Normal 17-mer 3Ј-FMdCMP 18-mer The appearance of cells with a sub-G 1 DNA content suggested that FMdC probably induced apoptosis in the leukemia cell lines. Morphological evaluation and a DNA fragmentation assay were used to explore this possibility. As shown in Fig. 5A , morphological changes typical of apoptosis, including cell shrinkage, condensation, and fragmentation of nuclei, and cell membrane blebbing, were observed in HL-60 cells incubated with FMdC. Apoptosis became apparent after 8 h of incubation with 0.1 M FMdC or 4 h of incubation with 1 M compound. These time courses were consistent with those of nucleosomal DNA fragmentation (Fig. 5B) . At a lower concentration (10 nM), no apparent apoptotic morphology was observed up to 24 h (data not shown), although this concentration of FMdC did cause a moderate arrest of the cells at S phase (Fig. 4) .
To determine whether incorporation of FMdC into DNA was a key event in triggering apoptosis, we incubated HL-60 cells with FMdC in the presence of aphidicolin, a potent inhibitor of DNA replication. Such treatment would be expected to limit the incorporation of a nucleoside analog into DNA. HL-60 cells were incubated with 1.0 FMdC for 4 h after exposure to various concentrations (0.03-1.0 M) of aphidicolin for 2 h. Under these experimental conditions, aphidicolin inhibited FMdC-induced DNA fragmentation in a concentration-dependent manner. In contrast, aphidicolin alone (0.1 and 1.0 M) did not induce DNA fragmentation (Fig. 5C ).
Discussion
Incorporation into DNA is the most prominent action of nucleoside analogs and is closely correlated with cytotoxicity (Kufe et al., 1984; Huang et al., 1990 , Xie and Plunkett, 1995 . In many cases, such incorporation causes a disturbance of DNA synthesis that is characterized by in vitro assays as a kinetic delay of DNA chain elongation at or near the sites of the incorporated analogs. The relative potency of the chain termination effect varies among different analogs, and there may be an apparent discrepancy in chain termination observed in vitro and in whole cells. For instance, the deoxyadenosine analog fludarabine shows potent DNA chain termination activity both in vitro and in whole cells (Huang et al., 1990) , whereas the deoxycytidine analog 1-␤-D-arabinofuranosylcytosine was effective in terminating DNA synthesis in vitro but was incorporated mainly internally into cellular DNA in cell culture (Kufe et al., 1984; Grant, 1998) . Another deoxycytidine analog, gemcitabine, is incorporated into the C sites of the elongating DNA strand and can be extended by a normal deoxynucleotide in vitro before DNA synthesis pauses . Consistent with this molecular pharmacological behavior, gemcitabine nucleotide is also found internally in DNA extracted from cells after incubation with this nucleoside analog.
The present study demonstrated that FMdCTP was incorporated into the C sites by DNA pol ␣ (Fig. 1) . Once FMdCTP was incorporated into the DNA, it potently terminated further DNA strand elongation (Fig. 2) . These findings are in contrast to the action of gemcitabine nucleotide, which can be extended by pol ␣ and pol ⑀, and which is found predominantly (Ͼ95%) in phosphodiester linkage in DNA extracted from whole cells . In our study, the competing normal nucleotide dCTP seemed to be preferred to FMdCTP by pol ␣ (Fig. 1A) and was selected over FMdCTP almost exclusively by pol I (Fig. 1B) . Therefore, it is likely that the ratio of dCTP to FMdCTP in cells can be used to predict the amount of analog incorporation into DNA. The extent to which FMdCDP can inhibit ribonucleotide reductase and thereby decrease the dCTP levels in whole cells may significantly alter the cellular FMdCTP/dCTP ratio to enhance the incorporation of FMdCTP. In designing a therapeutic strategy, a biochemical modulation approach that decreases dCTP levels, such as those using either fludarabine (Gandhi et al., 1993) or chlorodeoxyadenosine (Gandhi et al., 1996) may be usefully applied to FMdC. It should be pointed out that although FMdC nucleotide seemed to be a potent DNA chain terminator in vitro when DNA pol ␣ is used as the catalyzing enzyme, it is possible that other DNA polymerases in the cells might be able to extend the DNA substrate containing FMdCMP at 3Ј end. This possibility can be tested both in vitro by using various types of purified DNA polymerases, and in whole cells by using radioactive labeled FMdC to determine the location of the incorporated analog in DNA (terminal or internal incorporation).
Because incorporation of nucleotide analogs into DNA is a critical event in causing cytotoxicity, their excision from cellular DNA by a 3Ј 3 5Ј exonuclease activity is presumably an important mechanism in cell resistance to nucleoside analogs. Several cellular molecules, including DNA pol ␦, pol ⑀, and wt p53, have intrinsic 3Ј 3 5Ј exonuclease activity (Mummenbrauer et al., 1996; Burgers, 1998; Huang, 1998) . The present study demonstrated that neither pol ⑀ nor p53 effectively removed the incorporated FMdCMP from DNA in vitro (Fig. 3) . The kinetic analysis revealed an interesting interaction between the drug-containing DNA and pol ⑀ or p53. As shown in Table 1 , p53 and pol ⑀ were each able to bind with a much higher affinity to the FMdCMP-containing oligomer than to the normal oligodeoxynucleotide. However, the rate of analog excision was slow, as evidenced by the V max values, which were lower for the FMdCMP oligodeoxynucleotide than the normal oligodeoxynucleotide. These kinetic data suggest that once incorporated into the DNA, FMdCMP might have caused a change in the DNA configuration at the 3Ј terminus so that the analog-DNA was preferentially recognized by the proofreading exonuclease of pol ⑀ or p53. Importantly, this preferential binding did not result in an effective excision; this failure also may have been due to an analog-induced structural change at the 3Ј terminus that was unfavorable for the excision process. This interesting phenomenon has also been observed with the purine nucleoside analog fludarabine (Kamiya et al., 1996) . The findings that 3Ј-terminal FMdCMP is a poor substrate for extension, and that it is resistant to excision indicate that the analog is likely to be a strong DNA chain-terminating nucleotide in whole cells. This attribute is likely to have implications for mechanism-based combination strategies aimed at increasing nucleotide analog incorporation into the DNA of cells undergoing excision repair processes (Sandoval et al., 1996; Yang et al., 2000) .
The wt p53 is known to signal apoptosis in response to DNA damage. It is possible that the interaction of p53 with the analog-containing DNA serves as a signal to initiate apoptosis, thus making the cells more sensitive to nucleoside analogs. The high binding affinity of p53 to 3Ј FMdCMPoligodeoxynucleotide and low excision rate make this possibility more likely. Compared with the p53-null HL-60 cells, the wt p53 cells (ML-1) seemed to be more sensitive to FMdC (Fig. 4A ). In fact, previous studies demonstrated that transfection of p53-null (H1299) cells with wt p53 increased the sensitivity of the cells to the deoxycytidine analog gemcitabine (Feng et al., 2000) . In a separate experiment, we showed that the levels of p53 protein in ML-1 cells increased as early as 4 h after FMdC incubation (10 nM), and the p53 protein accumulation increased in a time-dependent manner (up to 24 h after drug treatment; data not shown). Thus, it is possible that the binding of p53 to the FMdCMP-containing DNA may serve as a signal to accelerate apoptosis. However, the greater sensitivity observed in ML-1 cells should not be solely attributed to their wild-type p53 status, because there may be other differences between ML-1 and HL-60 cells. Factors including drug metabolism, pharmacodynamic factors, and DNA repair capacity may potentially affect the cellular response to FMdC treatment.
Interestingly, in the HL-60 cell line, incubation with FMdC caused a moderate accumulation of cells in the S-phase before the cells succumbed to apoptosis (Fig. 4B ). This pause of cells in the S phase may reflect the early cellular response to the drug-induced inhibition or chain termination of DNA synthesis. The concomitant appearance of apoptotic cells (i.e., sub-G 1 population) and the decrease of S or G 1 phase cells suggests that the apoptotic cells were derived from the Sphase cell population. The moderate accumulation of cells in the G 1 phase observed in ML-1 cells (wt p53) might reflect the activation of p53 in response to the drug treatment. As described above, incubation of ML-1 cells with 10 nM FMdC led to a time-dependent accumulation of p53 protein, suggesting this molecule is likely to be involved in the cellular response to FMdC. Interestingly, under the same drug incubation conditions (10 nM FMdC for up to 24 h), no significant change in p21 protein was observed (data not shown). Further studies are needed to assess the molecular mechanisms responsible for the different cell-cycle disturbances caused by FMdC in various cell lines.
The important role of FMdC incorporation into DNA in causing cytotoxicity was further demonstrated in our experiments with aphidicolin, a potent inhibitor of DNA replication. Although inhibition of DNA synthesis by aphidicolin alone did not affect cell viability, incubation of cells with aphidicolin before the addition of FMdC to prevent incorporation of the analog substantially reduced FMdC-induced apoptosis (Fig. 5C ). This result suggests that incorporation of FMdC into DNA is a critical event in triggering apoptosis. This observation was consistent with the reported actions of other nucleoside analogs, such as fludarabine and gemcitabine, whose incorporation into cellular DNA is also essential in causing cell death (Huang et al., 1990 .
In summary, our study indicates that incorporation of FMdC into DNA is a key biochemical event responsible for the cytotoxic action of this analog against tumor cells. FMdC was incorporated into the C site of the DNA strain. Once FMdC nucleotide was incorporated into DNA, further extension of the 3Ј-FMdCMP-DNA strand by DNA polymerases was difficult. The incorporated analog seemed to be resistant to excision by the 3Ј 3 5Ј exonuclease activity of pol ⑀ and p53. The chain-termination activity of FMdC is likely to cause cells to pause in the S phase of the cell cycle and ultimately lead the initiation of processes that promote cell death. It is also possible that if the wild-type p53 protein is present in the cells, the terminally incorporated FMdC residues in DNA may serve as a mechanism to activate p53, trigger cell cycle arrest in G 1 /S boundary, and ultimately lead to cell death due to failure in removing the incorporated analog from DNA.
